In a recent Journal for Clinical Studies article, Aman Khera and Henry J. Riordan, Ph.D., discuss recent guidance, operational processes, and best practices designed by regulatory bodies to accelerate drug product development during COVID-19.
Authors:
Henry J. Riordan, PhD
Chief Development Officer
Aman Khera, MBA, FTOPRA, FRAPS
VP, Regulatory Science, Strategy and Innovation
